Advertisement

Topics

Latest "Odonate Therapeutics" News Stories

09:12 EDT 20th September 2018 | BioPortfolio

Here are the most relevant search results for "Odonate Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Odonate Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Odonate Therapeutics for you to read. Along with our medical data and news we also list Odonate Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Odonate Therapeutics Companies for you to search.

Showing "Odonate Therapeutics" News Articles 1–25 of 7,800+

Extremely Relevant

Odonate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will present at the Jefferies 2018 Global Healthcare Conference on Wednesday, June 6, 2018, at 2:30 p.m. Eastern Time. About Odon...


Relevant

Odonate Therapeutics Inc ODT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13032018] Prices from USD $250

SummaryOdonate Therapeutics Inc Odonate, formerly known as Odonate Therapeutics LLC, is a pharmaceutical company which develops medicines for the treatment of cancer. It develops best in class medicines that enhance and extend the lives of patients suffering from cancer. Odonate's lead product candidate, tesetaxel, is a novel orally administered taxane used for the treatment of various cancers. Te...

Odonate Therapeutics Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that there will be two poster presentations on tesetaxel at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 1 – 5, 201...


Odonate Therapeutics Inc ODT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23042018] Prices from USD $250

SummaryOdonate Therapeutics Inc Odonate, formerly Odonate Therapeutics LLC, is a pharmaceutical company which develops medicines for the treatment of cancer. Its lead product candidate, tesetaxel, is a novel orally administered taxane used for the treatment of advanced or metastatic breast cancer. Taxanes are class of anticancer agents that destroy cancer cells by preventing them from entering mit...

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three months ended March 31, 2018. As of March 31, 2018, Odonate had $195.2 million in cash, compared to $198.1 mil...

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2018

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2018. As of June 30, 2018, Odonate had $177.4 million in cash, compared to $198...

Tesetaxel, Administered Orally as a Single Agent, Results in 45% Confirmed Response Rate in Patients with HER2 Negative, Hormone Receptor Positive, Metastatic Breast Cancer

- Results from Multicenter Phase 2 Study Presented at The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting - Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that results from a m...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases Read more...

Technical Perspectives on Biotech Stocks -- Adaptimmune Therapeutics, Akebia Therapeutics, ...

www.wallstequities.com/registration Adaptimmune Therapeutics Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC rose slightly by 0.41%, ending Wednesday's trading session at $12.39. The stock Read more...

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...Read More... The post M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin appeared first on Drug Development Technology.

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Anika Therapeutics currently has a consensus target price of $62.50, indicating a potential upside of 16.84%.

Q Therapeutics, ReproCELL form MAGiQ, a CNS diseases JV

Fellow cell therapy companies Q Therapeutics Inc. and ReproCELL Inc. formed a 50/50-owned CNS disease-focused joint venture, ...

Small-Cap Snapshot: Galectin Therapeutics flies after receiving a patent for treating pulmonary fibrosis

Aquinox Pharmaceuticals, Summit Therapeutics and Global Blood Therapeutics are also making news

Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics

Pliant Therapeutics has raised $62m through a series B financing round from Cowen Healthcare Investments. The funding round also included participation...Read More... The post Deals and M&As this week: Pliant Therapeutics, MolMed, Modus Therapeutics appeared first on Drug Development Technology.

Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics

Celsius Therapeutics has raised $65m in a series A financing round led by Third Rock Ventures with participation from Google Ventures,...Read More... The post Deals this week: Celsius Therapeutics, Xenikos, Nohla Therapeutics appeared first on Drug Development Technology.

Alexion to Acquire Wilson Therapeutics and its Rare Liver Disorder Drug

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Wilson Therapeutics AB (publ) announced today that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. Wilson Therapeutics is a biopharmaceutical com...

Novartis, Pear Therapeutics to Develop Digital Therapeutics for Patients With Schizophrenia, MS

NewsNovartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients.

Juno Therapeutics Spinout Raises $90M

JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.

iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Probably Relevant

iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., to...

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng). Existing investor Lilly Asian Ventures (LAV)...Read More... The post Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics appeared first on Drug Development Technology.

Abeona Therapeutics Inc: Abeona Therapeutics gibt Finanzergebnisse und Geschäftserfolge des 4. Quartals 2017 bekannt

Telefonkonferenz für Anleger am Dienstag, 27. März um 10.00 Uhr ET NEW YORK und CLEVELAND (USA), 19. März 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), ein führendes, in der kli...

Nabriva Acquires Zavante Therapeutics and its Late-Stage Antibiotic

Shares of Nabriva Therapeutics are rising this morning after the company announced it acquired privately-held Zavante Therapeutics.

Novelion Therapeutics Inc.: Novelion Therapeutics Supports World Lipodystrophy Day

VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals ...

Technical Perspectives on Biotech Stocks -- Aimmune Therapeutics, Atara Biotherapeutics, ...

www.wallstequities.com/registration Aimmune Therapeutics Brisbane, Californiaheadquartered Aimmune Therapeutics Inc.'s stock finished last Friday's session 2.01% lower at $31.65. A total volume of 2.02 million Read more...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks